Antisense Research and Application

  • Stanley T. Crooke

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 131)

Table of contents

  1. Front Matter
    Pages I-XXVI
  2. P. D. Cook
    Pages 51-101
  3. A. A. Levin, D. K. Monteith, J. M. Leeds, P. L. Nicklin, R. S. Geary, M. Butler et al.
    Pages 169-215
  4. P. J. Schechter, R. R. Martin
    Pages 233-241
  5. A. M. Krieg
    Pages 243-262
  6. F. Kalkbrenner, B. Wittig, G. Schultz
    Pages 341-369
  7. C. F. Bennett, T. P. Condon
    Pages 371-393
  8. D. Fabbro, M. Müller, T. Geiger
    Pages 395-425
  9. S. L. Hutcherson
    Pages 445-462
  10. P. E. Nielsen
    Pages 545-560
  11. T. Akiyama, M. Hogan
    Pages 561-610
  12. Back Matter
    Pages 611-630

About this book


Antisense technology may result in dramatic changes in the therapy of many diseases and may provide tools to dissect pharmacological processes and to confirm the roles of various genes. In this volume, progress in the understanding of antisense technology and its use in creating new drugs is discussed. Potential caveats, pitfalls and limitations of the technology are also presented. In the next few years the pace at which new molecular targets will be identified will increase exponentially as the sequencing of the human genome and of other genomes proceeds.


Anti-Sense Antisense Oligonuclotide Pathobiochemie Therapie dopamine medicinal chemistry oligoneucleotides therapeutics

Editors and affiliations

  • Stanley T. Crooke
    • 1
  1. 1.ISIS Pharmaceuticals, Inc.Carlsbad Research CenterCarlsbadUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1998
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-63730-8
  • Online ISBN 978-3-642-58785-6
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods